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Abstract
This article revisits the links between psychopathology 
and functional gastrointestinal disorders such as 
irritable bowel syndrome (IBS), discusses the rational 
use of antidepressants as well as non-pharmacological 
approaches to the management of IBS, and suggests 
guidel ines for the treatment of IBS based on an 
interdisciplinary perspective from the present state of 
knowledge. Relevant published literature on psychiatric 
disorders, especially somatization disorder, in the context 
of IBS, and literature providing direction for management 
is reviewed, and new directions are provided from 
findings in the literature. IBS is a heterogeneous 
syndrome with various potential mechanisms responsible 
for its clinical presentations. IBS is typically complicated 
with psychiatric issues, unexplained symptoms, and 
functional syndromes in other organ systems. Most IBS 
patients have multiple complaints without demonstrated 
cause, and that these symptoms can involve systems 
other than the intest ine, e.g. bones and jo ints 
(fibromyalgia, temporomandibular joint syndrome), heart 
(non-cardiac chest pain), vascular (post-menopausal 
syndrome), and brain (anxiety, depression). Most IBS 
patients do not have psychiatric illness per se, but 
a range of psychoform (psychological complaints in 
the absence of psychiatric disorder) symptoms that 
accompany their somatoform (physical symptoms in the 
absence of medical disorder) complaints. It is not correct 
to label IBS patients as psychiatric patients (except those 
more difficult patients with true somatization disorder). 
One mode of treatment is unlikely to be universally 
effective or to resolve most symptoms. The techniques 
of psychotherapy or cognitive-behavioral therapy can 
allow IBS patients to cope more readily with their illness. 
Specific episodes of depressive or anxiety disorders 
can be managed as appropriate for those conditions. 
Medications designed to improve anxiety or depression 
are not uniformly useful for psychiatric complaints in IBS, 
because the psychoform symptoms that sound similar 
to those seen in psychiatric disorders may not have the 
same significance in patients with IBS.
© 2007 The WJG Press. All rights reserved.
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Functional medical disorders, by definition, lack objective 
physical, metabolic, or neurological explanations for their 
symptom presentations. Diagnosis of  these disorders, 
like diagnosis of  psychiatric disorders, is based entirely 
on subjective complaints. This may have contributed 
to longstanding conceptual izations of  functional 
disorders as fundamentally psychiatric or psychological 
in origin, cloaking this class of  disorders with a negative 
stigma. Although irritable bowel syndrome (IBS) may 
be considered an archetype among the functional 
gastrointestinal disorders, a wide variety of  medical 
syndromes and disorders in many medical subspecialties 
are also characterized by lack of  objective indicators 
and subject ive deter mination of  diagnosis. Non-
ulcer dyspepsia, premenstrual syndrome, chronic pain 
syndromes, tension headaches, fibromyalgia, chronic 
fatigue syndrome, interstitial cystitis, reflex sympathetic 
dystrophy, temporomandibular joint syndrome, and various 
chemical and food sensitivities are examples of  functional 
disorders in many organ systems.
Despite longstanding assumptions about psychiatric 
origins of  functional disorders, few gastroenterologists 
as recently as 15 years ago used psychopharmacologic 
agents to treat functional gastrointestinal disorders. Clouse 
and Lustman[1] observed that recognition of  the utility of  
antidepressant agents for functional disorders, especially 
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IBS, precipitated a rise in the use of  antidepressants in 
treatment of  functional gastrointestinal disorders. Now, in 
2007, the treatment of  these disorders with antidepressants 
by gastroenterologists is quite common, and as many 
as one in eight patients with these disorders are offered 
psychopharmacological agents.
Recently increasing application of  psychopha-
rmacotherapy for functional gastrointestinal disorders 
has further confused clinicians trying to manage these 
poorly understood functional syndromes with historical 
biases toward assumptions of  psychiatric origins. The use 
and effectiveness of  antidepressants may further solidify 
long-held beliefs that functional gastrointestinal disorders 
are really psychiatric. The well-known association of  
psychiatric illness and functional gastrointestinal disorders 
further contributes to assumptions of  psychopathology 
inherent in these disorders.
This article revisits the linkes between psychopathology 
and functional gastrointestinal disorders such as IBS and 
will discusses the rational use of  antidepressants as well as 
non-pharmacological approaches such as psychotherapy 
and psychoeducational/behavioral approaches in the 
management of  IBS. This article will also suggests guidelines 
for the treatment of  IBS from an interdisciplinary (psychology, 
psychiatry, and gastrointestinal/internal medicine) 
perspective based on the present state of  knowledge.
THE PSYCHIATRIC ANGLE
Psychiatric disorders are prevalent in medical practice, 
especial ly in primary care, where as many as one-
third of  patients may suffer from one or more current 
diagnosable psychiatric disorders, especially depressive 
and anxiety disorders[2-5]. Among patients with functional 
gastrointestinal disorders, the rates of  associated 
psychiatric disorders are even higher. In the case of  IBS, 
50%-90% of  those seeking treatment have been found to 
also have comorbid lifetime psychiatric disorders, especially 
depressive and anxiety disorders[6]. Somatization disorder 
(SD) is also highly relevant to functional gastrointestinal 
disease. This is not only because of  documented 
prevalence rates of  somatization disorder in 15% to 
48% among IBS patient samples[7-12], but also because of  
implications introduced by the presence of  somatization 
disorder for classification and understanding of  IBS and 
probably also other functional disorders as well.
Abnormal cytokine production has been found 
in association with IBS[13], major depression[14,15], and 
somatization disorder[16]. These findings suggest a potential 
unifying mechanism connecting events in the nervous 
system (central or enteric) with IBS symptoms (e.g. 
fatigue, myalgia, sleep disturbance). The cytokine findings, 
however, have not been consistently reproducible, nor 
have they been correlated well with individual symptoms.
Somatization disorder, a well-validated psychiatric 
disorder, is the anchor of  the diagnostic category of  
somatoform disorders[17]. Somatization disorder shares 
many clinical features with IBS. Like other psychiatric 
disorders and functional disorders, somatization disorder 
lacks biological markers and is diagnosed based on 
subjectively reported symptoms [18]. The diagnosis of  
somatization disorder is defined by patient report of  
multiple subjective symptoms across multiple organ 
systems, often collected over time and across settings, 
because patients usually do not divulge all their symptoms 
at once to one interviewer[11,19]. Qualifying symptoms for 
the diagnosis are formally defined as physical complaints 
that on the surface seem to represent medically based 
problems, but upon sufficient medical investigation defy 
full medical explanation[20]. Thus, the term “somatoform” 
means, literally, symptoms resembling physical illness. 
Although somatoform symptoms have historically been 
considered to represent physical expression of  psychological 
distress [21-23], these notions are not demonstrated by 
empirical research, and somatization disorder and 
somatoform symptoms are defined without assumption of  
psychological mechanisms.
Somatization disorder patients complain of  many 
medical ly unexplained gastrointest inal and other 
bodily symptoms, such as neurological, sexual, and 
pain symptoms, as well as psychiatric symptoms. The 
line between IBS and somatization disorder is further 
blurred by the frequent occurrence of  other comorbid 
functional disorders in patients with IBS[24]. Multivariate 
analyses suggest that comorbid functional syndromes 
are distinct disorders and not necessarily manifestations 
of  one common disorder (e.g., somatization disorder), 
having features in common that lead to symptom 
reporting. Although the specific prevalence of  IBS and 
other functional gastrointestinal disorders in patients 
with somatization disorder is not known, analysis of  a 
large population study database indicated that virtually all 
individuals diagnosed with somatization disorder and few 
of  those without somatization disorder acknowledged 
two or more medically unexplained gastrointestinal 
symptoms[25].
Patients with somatization disorder often do not 
confine their medically unexplained symptoms to the 
physical domains. Most also complain of  many symptoms 
of  many psychiatric disorders they do not actually 
have. Patients with somatization disorder have been 
demonstrated to report as many as, or more, symptoms 
of  major depression, anxiety disorders, and schizophrenia 
than patients who actually suffer from these disorders[26-28]. 
These well documented psychiatric symptoms in these 
patients who do not have the psychiatric disorders 
assoc ia ted wi th the symptoms they repor t have 
been termed “psychoform,” in parallel to the term 
“somatoform” referring to symptoms suggesting bodily 
illness that is not present[19,29,30].
Consistent with these symptom-reporting patterns, 
the medical histories of  patients with somatization 
disorder typically reflect multiple medical and psychiatric 
diagnoses, often including various functional disorders[19]. 
The more functional disorders a patient has, the more 
likely is the diagnosis of  somatization disorder[11]. When 
IBS or other functional disorders occur in patients with 
somatoform disorders, the gastrointestinal complaints are 
counted toward the diagnosis of  SD because of  the lack 
of  objective indicators of  medical illness[20]. Patients with 
somatization disorder may also have many complaints 
of  allergic reactions and medication intolerances, consult 
multiple physicians in many specialties, have histories of  
multiple failed treatments, and generally follow a difficult 
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course of  treatment and patient-physician interactions[19]. 
Patients with somatization disorder typically exhibit a 
pattern of  symptom expression recurrently throughout 
most of  their lives, regardless of  their current mood 
state, unlike patients with depressive disorders, who 
often have medically unexplained complaints during 
depressive episodes but not at other t imes [20]. No 
psychopharmacologic agent has been demonstrated to be 
effective in alleviating somatization disorder[19,31], although 
some patients may benefit from the usual treatments 
for established comorbid psychiatric illnesses that are 




Clinicians and researchers have observed that patients with 
IBS or other functional gastrointestinal disorders tend 
to have additional functional disorders in various other 
organ systems, multiple somatoform symptoms distributed 
across most physical categories (e.g., unexplained pain; 
neurological symptoms such as paralysis, imbalance, and 
weakness; and sexual complaints), and complaints of  
multiple drug allergies and sensitivities. The previously 
mentioned comorbid psychopathology, especial ly 
depressive and anxiety syndromes, are consistent with 
these patients’ patterns of  complaints of  many types, 
including psychiatric. Many of  these patients also engage 
in unusually frequent health care visits, undergo multiple 
diagnostic tests and surgical procedures, use many over-
the-counter and prescription medications, and become 
refractory to treatment[33]. Treatment of  refractory 
functional gastrointestinal disorders has been described as 
difficult and frustrating[33-35].
It is perhaps more than just coincidental that these 
characteristics of  patients with IBS and other functional 
gastrointestinal disorders have many features in common 
with the classic features of  patients with somatization 
disorder described earlier in this article. It has been 
previously hypothesized that the psychiatric comorbidity 
in IBS patients may reflect the inclusion of  somatization 
disorder in IBS samples[36,37]. North and colleagues[11,19] 
further hypothesized that other clinical perceptions of  
IBS patients may be colored by prominent characteristics 
of  the somatization disorder patients within their 
ranks. Indeed, examination of  IBS patients segregated 
by the presence or absence of  somatization disorder 
demonstrated that IBS patients had more abnormal 
illness behavior and psychiatric symptoms compared 
to patients with IBS alone, and patients with IBS alone 
were similar to a comparison group of  ulcerative colitis 
patients on these characteristics[11,12]. Additionally, IBS 
patients with somatization disorder had significantly more 
gastrointestinal and other symptoms, psychiatric disorders, 
physicians consulted, telephone calls to physicians, 
urgent care visits, medication changes, missed work 
days, benzodiazepine use, poor treatment outcomes, and 
treatment dissatisfaction compared to their counterparts 
without somatization disorder[11]. These findings suggest 
one important point that IBS may be a heterogeneous 
concept, namely through its frequent association with 
somatization disorder.
The dimensional construct of  somatization outside 
the context of  the disorder based on its name reflects 
a need for further explication of  medically unexplained 
symptoms in diverse settings. Outside of  somatization 
disorder, the concept of  somatization conceptualized 
as a process or a behavior is poorly understood. 
Somatoform syndromes not meeting full criteria for 
somatization disorder are recognized in formal diagnostic 
nomenclature[20], representing a residual category for 
persistent somatoform presentations lasting at least six 
months that do not meet somatization disorder criteria 
(undifferentiated somatoform disorder) and a category 
for unexplained physical complaints of  less than six 
months’ duration (somatoform disorder not otherwise 
specified). However, these diagnoses are not diagnostically 
validated. Thus, the field does not really know what do to 
with medically unexplained symptoms that are not part 
of  somatization disorder. The symptom of  low mood 
which we call “depression” is not synonymous with the 
diagnosis of  major depression; depressed mood also 
occurs in dysthymic disorder and even in normal people 
and does not necessarily reflect the same processes as 
those occurring when this symptom is part of  a major 
depressive episode. Similarly, “somatization” behavior 
outside of  somatization disorder may be a very different 
phenomenon from behavior bearing the same name that 
defines somatization disorder.
Outside diagnostic constructs that characterize 
longstanding trait-related phenomena, the concept of  
somatization has come to represent state-dependent 
behavior in the context of  psychological stress. Thus, 
the term “somatization” has accumulated a baggage 
of  assumptions of  psychological processes beyond the 
defining lack of  medical explanation for the symptoms 
of  the disorder bearing its name. It is likely that features 
of  “somatization” observed in functional medical 
disorders are actually contaminated with characteristics 
of  unrecognized cases of  somatization disorder among 
the patients. Among patients presenting with medically 
unexplained symptoms who also have psychiatr ic 
illness, the likelihood of  having a somatoform disorder 
is remarkably high [2]. Because we do not know the 
etiology of  medically unexplained symptoms outside 
validated somatoform disorders, “somatization” is a 
loaded term implying processes that may not apply, and 
thus terminology less burdened by assumptions such as 
“complaints without nonpsychiatric illness” may provide a 
more careful way to discuss these symptoms.
GENERAL APPROACH TO EFFECTIVE 
MANAGEMENT OF FUNCTIONAL 
GASTROINTESTINAL DISORDERS
IBS complaints without psychiatric illness
Many patients with IBS or other functional gastrointestinal 
disorders present extraordinary management problems 
for physicians. They absorb a great deal of  time, and 
need more physician empathy, reassurance, explanation, 
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attention, and time for emotional ventilation than the 
average patient. Gastrointestinal symptoms may restrict 
their activities, change their self-image, and present a 
source of  worry and embarrassment. The impact may be 
very psychological and stress-provoking. Because of  these 
lifestyle and personal worries, psychological counseling, 
education and encouragement are the universal approaches 
with all IBS patients regardless of  the level of  severity and 
chronicity. Patients should generally be advised that they 
have a “medical problem” which is complex and at times 
difficult to treat. Patients can also be told that there may 
be psychological ramifications as well which can make 
the gastrointestinal symptoms more difficult to tolerate, 
and that psychiatric symptoms and disorders frequently 
accompany the gastrointestinal disorder.
The management of  IBS calls for the best “bedside” 
manner of  physicians as they need to approach this 
problem medically, yet at the same time, recognizing 
the psychological and psychiatric issues that so often 
accompany it. Being unwilling to credit the symptoms 
of  patients with true somatic content, being dismissive 
of  patients and calling their syndrome psychiatric (“all 
in your head”) or simply referring them to psychiatric 
professionals (without retaining the role as primary care 
physician) denies the complex nature of  the syndrome and 
falsely relegates the syndrome to a failure of  the patient's 
will. This whole issue becomes even more complex if  
the expertise of  a mental health professional is needed. 
Patients are better served if  they are prepared for referral 
to a psychiatrist or psychologist. “Let’s see if  psychological 
procedures or psychiatric medications can further improve 
or alleviate your symptoms in addition to your other 
treatments.” Treatment goals should stress solutions to 
these troubling symptoms and provide behavioral-cognitive 
strategies for coping. It is important to decide whether 
to focus on the pain and bowel symptoms alone, or to 
include other somatic and/or psychiatric symptoms in the 
treatment goal. This decision will depend on the patient 
and the presence or absence of  associated symptoms, 
whether or not they form a diagnostic cluster for a co-
morbid condition. When indicated, the use of  specific 
medications for pain (e.g. tricyclics, serotonin-selective 
agents, SSRIs), or bowel function (e.g. serotonergic drugs, 
opiates), may be useful (see section on “Psychotropic 
Medication”).
IBS with somatization disorder 
Most IBS and other functional gastrointestinal disease 
can be managed with this kind of  patience and logical 
problem-solving approaches. More refractory illness, 
patients with more complex and difficult courses of  
treatment, and patients with many psychiatric problems 
may require reconsideration of  the potential for an 
underlying somatization disorder diagnosis. The diagnosis 
of  somatization disorder can be difficult and time-
consuming to document because the evidence does not 
present itself  at a single patient appointment[11,19]. The 
diagnosis may require lengthy history-taking as well as 
gathering considerable medical history and observation 
over time to develop cumulative evidence of  consistent 
patterns of  multiple symptom complaints in many 
organ systems. Psychiatric consultation can sometimes 
facilitate this process. Because the effective management 
of  somatization disorder hinges on recognition of  the 
syndrome, diagnosis is the essential cornerstone of  
treatment[19].
PSYCHOLOGICAL INTERVENTIONS
IBS complaints without nonpsychiatric illness
The goal of  psychotherapy is not to directly change or 
alter specific IBS target symptoms, but rather to promote 
coping and problem-solving skills and enhance the patient’s 
well being and ability to function. Behavioral and cognitive 
therapies are among the useful interventions. There is 
evidence from randomized controlled trials to suggest that 
psychotherapy may be as effective as serotonin-selective 
antidepressants for some patients and more cost-effective 
than antidepressant medication[38,39].
Formal psychotherapy is best left to mental health 
specialists, such as clinical psychologists and psychiatrists. 
Cognitive/behavioral therapy developed by Aaron Beck 
deals with patients’ irrational cognitive appraisals and 
assumptions that appear to underlie negative emotional 
states, offering counteractive strategies through rational 
self-talk to correct negative underlying cognitions. 
Generally, individuals likely to benefit from this type 
of  therapy harbor irrational negative thoughts about 
themselves and tend to catastrophize interpretations of  
interpersonal interactions and life events.
Cognitive-behavioral therapy and problem-solving 
techniques provide practical assistance to dealing with life’s 
problems. For patients suffering from IBS, what thoughts 
and coping skills will lead to better coping and functioning? 
Carrying a change of  clothes, preparing for problems and 
developing plans for solutions help to maintain or restore 
a sense of  control, which may improve both self-esteem 
and self-effectiveness. These procedures, though easy to 
conceive, theoretically are much harder to employ. Thus, 
for sufficient cognitive-behavioral and problem-solving 
help for recalcitrant IBS, referral to a well-trained mental 
health professional may be imperative.
IBS with somatization disorder
While many of  the procedures described above may 
be helpful for IBS patients with somatization disorder, 
somatization disorder can be very difficult to manage 
and may require assistance of  mental health expertise. 
The recommended treatment for somatization disorder 
revolves around orchestration of  medical care by one 
designated gatekeeper (not necessarily a psychiatrist) 
whose function is to keep the patient engaged in treatment 
to curtail doctor-shopping and iatrogenic morbidity 
resulting from medically inappropriate invasive diagnostic 
and surgical procedures and abusable medications. While 
this gatekeeper logically could be a psychiatrist, not all 
somatization disorder patients are willing to accept a 
psychiatric referral, although patients who have comorbid 
psychiatric symptoms or disorders may be more willing 
to accept a psychiatric referral. After a sufficiently 
comprehensive medical evaluation, pursuit of  further 
procedures should be based on objective evidence of  
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illness. The goal is not to cure somatization disorder, which 
is generally chronic and lifelong, but to divert the patient 
from iatrogenic harm and promote healthier functioning. 
Development of  a solid therapeutic relationship with the 
somatization disorder patient provides the social leverage 
to assist in redirecting the patient from repetitious litanies 
of  medical complaints to building problem-solving and 
coping skills to address their many interpersonal and 
social problems. Regular appointments with physical 
examinations are recommended to demonstrate physician 
interest in the patient’s concerns and circumvent 
symptom production as a requisite for physician contact. 
Patients can be reassured that medical evaluation of  their 
symptoms has eliminated serious and disabling disease and 
praised for their endurance of  suffering. A management 
focus based on long-term follow-up rather than pursuit 
of  further diagnostic procedures can allay patient fears, 
reduces medical costs, and improves patient satisfaction 
and well being[12,19,40]. Some of  these principles can also be 
helpful in management of  highly symptomatic or difficult 
IBS patients who do not meet diagnostic criteria for 
somatization disorder.
PSYCHOTROPIC MEDICATION
Many patients do not respond adequately to reassurance or 
education because of  temperament, character, or learning 
style. They may not respond to dietary and nutritional 
advice, as there is no specific dietary component that can 
be identified consistently in IBS patients[41]. Finally, patients 
may not respond to medications for gastrointestinal 
symptoms, either because the symptom does not derive 
from the intestine itself, or because non-gastrointestinal 
symptoms are dominant and not influenced by drugs 
directed at gastrointestinal function. For these groups 
of  patients, psychotropic medications may be helpful. 
The mainstay of  psychopharmacotherapy in functional 
gastrointestinal disease is antidepressant medication. 
Antidepressants are not just for treatment of  depression. 
These medications are also useful in the treatment 
of  anxiety disorders, pain syndromes, and functional 
disorders, even in patients without depression.
Evidence for the utility of  antidepressant medication 
in functional gastrointestinal disease has emerged from 
an increasing volume of  literature providing empirical 
support. Randomized clinical trials, however, provide little 
evidence that antidepressant therapy is superior to placebo 
as treatment for IBS[1]. Most of  the available studies are of  
low or moderate quality and do not demonstrate any clear-
cut advantage of  antidepressant therapy. Another difficulty 
in assessing clinical trials of  antidepressants for IBS is that 
most IBS patients do not require psychopharmacologic 
interventions because their symptoms are mild, infrequent, 
and only periodically troublesome. Short-term treatments, 
including over-the-counter preparations (e.g., laxatives, 
anti-diarrhea medicines, and anti-spasmodics), dietary 
modifications such as increased fiber, and behavioral 
management and encouragement, may be sufficient to 
manage most IBS symptoms. Antidepressant therapy is 
generally reserved for patients with more chronic and 
severe IBS.
In a meta-analysis reviewing twelve randomized 
placebo-controlled clinical trials, Jackson and colleagues[42] 
concluded that antidepressants appear to be effective in the 
treatment of  functional gastrointestinal disorders with a 
reported odds ratio exceeding 4.0. Unfortunately, however, 
three patients needed to be treated to improve one 
individual’s symptoms. A Cochrane database systematic 
review, selecting only two studies using a dichotomous 
endpoint for pain relief, four using such an endpoint for 
global relief, and two using a continuous outcome for 
pain, concluded there was no evidence of  an effect[43]. 
In a comprehensive review of  all agents for IBS, Jailwala 
et al[44] concluded from seven double-blinded placebo-
controlled and randomized studies that the evidence for 
global improvement using psychotropic agents is “based 
on a small number of  studies of  suboptimal quality”. In 
their recent comprehensive review of  antidepressants for 
functional gastrointestinal disorders, Clouse and Lustman[1] 
similarly cautioned that methodological issues may have 
biased many of  the conclusions of  these studies. Many 
of  the studies they reviewed were older and subject to 
criticisms of  methodological designs not meeting current 
research standards for clinical trials.
Most studies reviewed by Clouse and Lustman used 
tricyclic antidepressants (primarily amitriptyline) rather 
than the newer antidepressant classes such as SSRIs. 
Studies concluding antidepressant effectiveness often 
used outcome measures combining IBS target symptoms 
with quality of  life items and indicators of  depression and 
anxiety. The studies using narrower targets for outcome 
measures, such as principal IBS symptoms, found fewer 
treatment advantages for antidepressant medications. 
Studies of  antidepressant medications for functional 
gastrointestinal disease have also suffered from use of  
fixed dose protocols, an issue that is especially relevant 
for tricyclic antidepressant medications with their wide 
dosage range. In many of  these studies, nonpsychiatric 
physic ians (gastroenterologists and primary care 
providers) administered the antidepressant agents, further 
reducing the likelihood of  demonstrating benefit from 
antidepressant medication. In clinical practice, doses are 
tailored to the patient rather than fixed, and patients are 
heterogeneous. Though the accumulated research suggests 
some beneficial effects of  psychotropic medications with 
this population, it is difficult to make a clear judgment 
about their role with this population. At present, it is safest 
to conclude that clinical experience suggesting benefit of  
antidepressant medications in functional gastrointestinal 
disease is more persuasive than evidence from carefully 
executed randomized clinical trials.
How do antidepressants work?
Clouse and Lustman[1] recently observed that gastro-
enterologists now routinely prescribe antidepressant 
medication for treatment of  IBS. Talley [45] suggested 
that it may be ludicrous to believe that antidepressants 
directly treat the underlying pathology of  IBS. He noted 
that recent studies have demonstrated only that the older 
tricyclic antidepressants and the newer SSRI agents alike 
improve global measures of  outcome such as patient 
satisfaction and quality of  life, but do little to relieve 
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target IBS symptoms. In 1987, Clouse and Lustman[46] 
showed in a placebo-controlled study of  low-dose 
trazodone for patients with functional esophageal illness 
that trazodone reduced distress but did not improve 
the esophageal symptoms. Thus, patients felt better, but 
their gastrointestinal symptoms persisted. They likened 
the antidepressant approach to treatment as a “band-
aid” therapy. Not intuitively, response to antidepressant 
medication is not predicted by the presence of  a depressive 
or anxiety disorder[1].
The restoration of  normal intestinal motility and 
reduction of  intestinal sensitivity to food and other 
irritating substances by antidepressants would be expected 
to be relevant to treatment of  functional gastrointestinal 
disease. The mechanism of  antidepressants considered 
most relevant to functional gastrointestinal disease is their 
modification of  neurotransmitter activity. Antidepressants 
are powerful presynaptic blockers of  serotonin and 
norepinephrine in the brain, improving mood and 
reducing pain. It is thought that neurotransmitter actions 
of  antidepressants in the gut may also contribute to 
their therapeutic effects in IBS. Serotonin is found in the 
intestinal wall and in blood vessels, and its concentration 
is greatest in the enteric nervous system. Blockade of  
serotonin and norepinephrine in the enteric nervous 
system may function to reduce transmission of  messages 
to pain centers and thereby re-establish normal brain-
gut connections. Thus, serotonin could be an essential 
l ink between motil ity, sensation and the brain-gut 
connection. By increasing serotonin in both gut and 
brain, antidepressants could be expected to raise the 
threshold of  gut discomfort and pain and simultaneously 
facilitate emotional well-being. In patient studies of  
functional gastrointestinal illness, however, antidepressants 
have not been shown to have clinically significant 
effects on gut physiology or individual gastrointestinal 
symptoms, although global well-being does improve with 
antidepressant therapy[1,46]. 
IBS patients have elevated plasma serotonin levels, and 
IBS symptoms are more prominent after meals[47]. These 
findings have led some workers to consider serotonin 
central to the pathophysiology of  IBS. However, the 
peak increase in plasma serotonin is not well coordinated 
with the time when patients most often experience post-
meal symptoms (60-90 min after the meal) [48]. Other 
hormonal changes that occur following a meal include 
increased secretion of  cholecystokinin (CCK), glucagon-
like peptide 1 (GLP-1), and peptide YY (PYY) as well as 
decreased secretion of  ghrelin[49]. The degree of  these 
changes, however, is not altered in patients with functional 
gastrointestinal illness compared to controls.
Clinical use of antidepressants in the treatment of 
functional gastrointestinal disorders
The use of  ant idepressants in the t rea tment of  
functional gastrointestinal disorders has been described 
in detail in a recent review by Clouse and Lustman[1]. 
The physician should not expect these drugs to change 
gut motility or physiology or necessarily reduce target 
symptoms, but success in using these agents is best 
measured in terms of  functioning, quality of  life, well-
being, and patient satisfaction with treatment. In general, 
tricyclic antidepressants may convey some advantages 
over SSRIs for pain and for medically unexplained 
physical symptoms[50,51]. Choice of  antidepressant class 
can be aided by consideration of  side effect profiles 
(especially anticholinergic effects, sedation, weight 
gain, orthostasis, and cardiac conduction problems for 
tricyclics and activation and gastrointestinal distress 
for SSRIs). To reduce side effect burden, initial doses 
of  antidepressants should be low, e.g., 25-50 mg/d of  
tricyclic antidepressants, and even lower (e.g., 10 mg/d) 
for patients with somatization disorder. The dose should 
be gradually increased (by 10-15 mg/d every 5-7 d) until 
adequate response is achieved, sometimes requiring four 
weeks at psychiatric dosage. Patients least likely to have a 
good outcome with antidepressant therapy are those with 
constipation-predominant IBS, patients with objective 
indicators of  gastrointestinal motility delay, patients with 
medical comorbidities exacerbated by antidepressant 
medications, and patients with somatization disorder[1,39,52]. 
Patients with a good antidepressant response can be 
successfully maintained on antidepressant medications for 
months to years. Tapering the dosage before antidepressant 
withdrawal will minimize  likelihood of  discontinuation 
syndromes.
Ant idepressants a re g enera l l y not usefu l for 
somatization disorder, except for their utility for comorbid 
conditions. There is no medication specific for treatment 
of  somatization disorder. Patients with somatization 
disorder generally have more adverse reactions to 
medications and liability for misuse of  habit-forming 
medications.
CONCLUSION
IBS is a heterogeneous syndrome with many potential 
mechanisms responsible for its clinical presentations[53]. 
These mechanisms appear to relate to abnormal gut 
motil i ty, paral lel abnormalit ies of  enteric and/or 
central nervous system functioning, and even immune 
dysregulat ion. In the majority of  patients, IBS is 
complicated by psychiatric issues and unexplained 
symptoms and functional syndromes in other organ 
systems[1]. For these reasons, one mode of  treatment is 
unlikely to be universally effective or to resolve most 
symptoms.
It has become clear in recent years that the majority 
of  IBS patients have multiple complaints without 
demonstrated cause, and that these symptoms can affect 
systems other than the intestine, e.g. bones and joints 
(fibromyalgia, temporomandibular joint syndrome), heart 
(non-cardiac chest pain), vascular (post-menopausal 
syndrome), and brain (anxiety, depression). Viewed in this 
light, most IBS patients do not have psychiatric illness per 
se, but a range of  psychoform complaints that accompany 
their somatoform ones. It is not correct to label them 
as psychiatric patients (except those more difficult 
patients with true somatization disorder), but it appears 
to be valid to utilize the techniques of  psychotherapy or 
cognitive-behavioral therapy to allow them to cope more 
readily with their illness. Specific episodes of  depressive 
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or anxiety disorder can be managed as appropriate for 
those conditions. It is not surprising, therefore, that 
drugs designed to improve anxiety or depression are not 
uniformly useful for psychiatric complaints in IBS, because 
the psychoform symptoms that sound similar to those seen 
in psychiatric disorders may not have the same significance 
in patients with IBS.
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